spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Outsourcing in Clinical Trials West Coast

Outsourcing in Clinical Trials West Coast

3-4 March 2020
Hyatt Regency San Francisco Airport

Last year's event was attended by 700+ clinical trial stakeholders. Following its success, we are pleased to forecast the 2020 edition will be even in larger scale, with a great speaker line up and engaging content. This edition aims to give attendees practical take-aways which they can apply to their studies.

The 2020 programme has four dedicated streams:
Clinical Operations & Outsourcing
Technology & Innovation
Patient Engagement (NEW for this editions)
Medical Device Trials

Attendees will hear talks from Dan Trigub, Head of Uber Health - who will give details on how to remove transportation as a barrier to care, as well as a keynote presentation from Microsoft’s Clinical Research Innovation Hub.

web https://arena-international.com/octwestcoast/
email Hyatt Regency San Francisco Airport
 
Print this page
Send to a friend
   
spacer
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

White Papers

Quality Systems Guide

Research Quality Association

This guide concentrates on the core, underlying principles of quality that are pivotal – explicitly or implicitly – to all quality management standards that impact on research and development.
More info >>


News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement